Download PDF
Semin Neurol 2012; 32(05): 538-543
DOI: 10.1055/s-0033-1334476
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Recognition and Treatment of Neurologic Wilson's Disease

Matthew T. Lorincz
1   Department of Neurology, University of Michigan Health Systems, Ann Arbor, Michigan
› Author Affiliations
Further Information

Publication History

Publication Date:
15 May 2013 (online)

    Permissions and Reprints

Abstract

As Wilson's disease is both preventable and treatable, the diagnosis must not be missed. Despite this, it is usually misdiagnosed. Misdiagnosis and delay in treatment are clinically relevant because if left untreated, Wilson's disease progresses to hepatic failure or severe neurologic disability, and death. Those adequately treated have a normal life span. Wilson's disease is an autosomal recessive disease caused by mutations in the ATP7B gene. Mutations in ATP7B result in abnormal copper metabolism and subsequent toxic accumulation of copper. The clinical manifestations of neurologic Wilson's disease include variable combinations of dysarthria, dystonia, tremor, parkinsonism, ataxia, and choreoathetosis. Once the possibility of Wilson's disease is considered, diagnosis is straight forward. Currently available treatments, including zinc acetate and trientine, are generally well tolerated and effective.

Keywords

Wilson's disease - ceruloplasmin - copper - dysarthria - dystonia - tremor - parkinsonism - movement disorders
 

  • References

  • 1 Wilson S. Progressive lenticular degeneration: A familial nervous disease associated with cirrhosis of the liver. Brain 1912; 34: 295-509
    CrossrefPubMedGoogle Scholar
  • 2 Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine (Baltimore) 1992; 71 (3) 139-164
    PubMedGoogle Scholar
  • 3 Brewer GJ. Wilson's Disease: A Clinician's Guide to Recognition, Diagnosis, and Management. Boston, MA: Kluwer Academic; 2001
    Google Scholar
  • 4 Lorincz MT. Neurologic Wilson's disease. Ann N Y Acad Sci 2010; 1184: 173-187
    CrossrefPubMedGoogle Scholar
  • 5 Machado A, Chien HF, Deguti MM , et al. Neurological manifestations in Wilson's disease: report of 119 cases. Mov Disord 2006; 21 (12) 2192-2196
    CrossrefPubMedGoogle Scholar
  • 6 Taly AB, Meenakshi-Sundaram S, Sinha S, Swamy HS, Arunodaya GR. Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore) 2007; 86 (2) 112-121
    CrossrefPubMedGoogle Scholar
  • 7 Starosta-Rubinstein S, Young AB, Kluin K , et al. Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging. Arch Neurol 1987; 44 (4) 365-370
    CrossrefPubMedGoogle Scholar
  • 8 Svetel M, Kozić D, Stefanova E, Semnic R, Dragasevic N, Kostic VS. Dystonia in Wilson's disease. Mov Disord 2001; 16 (4) 719-723
    CrossrefPubMedGoogle Scholar
  • 9 Lang C. Is Wilson's disease a dementing condition?. J Clin Exp Neuropsychol 1989; 11 (4) 569-570
    CrossrefPubMedGoogle Scholar
  • 10 Lang C, Müller D, Claus D, Druschky KF. Neuropsychological findings in treated Wilson's disease. Acta Neurol Scand 1990; 81 (1) 75-81
    PubMedGoogle Scholar
  • 11 Dening TR, Berrios GE, Walshe JM. Wilson's disease and epilepsy. Brain 1988; 111 (Pt 5) 1139-1155
    CrossrefPubMedGoogle Scholar
  • 12 Wiebers DO, Hollenhorst RW, Goldstein NP. The ophthalmologic manifestations of Wilson's disease. Mayo Clin Proc 1977; 52 (7) 409-416
    PubMedGoogle Scholar
  • 13 Akil M, Brewer GJ. Psychiatric and behavioral abnormalities in Wilson's disease. Adv Neurol 1995; 65: 171-178
    PubMedGoogle Scholar
  • 14 Dening TR, Berrios GE. Wilson's disease: a longitudinal study of psychiatric symptoms. Biol Psychiatry 1990; 28 (3) 255-265
    CrossrefPubMedGoogle Scholar
  • 15 Burke JF, Dayalu P, Nan B, Askari F, Brewer GJ, Lorincz MT. Prognostic significance of neurologic examination findings in Wilson disease. Parkinsonism Relat Disord 2011; 17 (7) 551-556
    CrossrefPubMedGoogle Scholar
  • 16 Walshe JM, Yealland M. Chelation treatment of neurological Wilson's disease. Q J Med 1993; 86 (3) 197-204
    PubMedGoogle Scholar
  • 17 Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson's disease. Lancet 2007; 369 (9559) 397-408
    CrossrefPubMedGoogle Scholar
  • 18 van Wassenaer-van Hall HN, van den Heuvel AG, Algra A, Hoogenraad TU, Mali WP. Wilson disease: findings at MR imaging and CT of the brain with clinical correlation. Radiology 1996; 198 (2) 531-536
    PubMedGoogle Scholar
  • 19 Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 1987; 44 (5) 490-493
    CrossrefPubMedGoogle Scholar
  • 20 Brewer GJ, Hill GM, Prasad AS, Cossack ZT, Rabbani P. Oral zinc therapy for Wilson's disease. Ann Intern Med 1983; 99 (3) 314-319
    CrossrefPubMedGoogle Scholar
  • 21 Hoogenraad TU. Paradigm shift in treatment of Wilson's disease: zinc therapy now treatment of choice. Brain Dev 2006; 28 (3) 141-146
    CrossrefPubMedGoogle Scholar
  • 22 Brewer GJ, Askari F, Lorincz MT , et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006; 63 (4) 521-527
    CrossrefPubMedGoogle Scholar
  • 23 Hoogenraad TU, Koevoet R, de Ruyter Korver EG. Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration). Eur Neurol 1979; 18 (3) 205-211
    CrossrefPubMedGoogle Scholar